109 related articles for article (PubMed ID: 16526183)
21. High bone turnover but normal bone mineral density in women suffering from schizophrenia.
Bergemann N; Parzer P; Mundt C; Auler B
Psychol Med; 2008 Aug; 38(8):1195-201. PubMed ID: 18366816
[TBL] [Abstract][Full Text] [Related]
22. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
23. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
24. Bone mineral density and osteoporosis risk in older patients with schizophrenia.
Jung DU; Kelly DL; Oh MK; Kong BG; Kang JW; Lee SJ; Shim JC
J Clin Psychopharmacol; 2011 Aug; 31(4):406-10. PubMed ID: 21694624
[TBL] [Abstract][Full Text] [Related]
25. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
26. Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy.
Beerhorst K; Tan IY; De Krom M; Verschuure P; Aldenkamp AP
Acta Neurol Scand; 2013 Oct; 128(4):273-80. PubMed ID: 23461582
[TBL] [Abstract][Full Text] [Related]
27. Bone mineral density of vegetarian and non-vegetarian adults in Taiwan.
Wang YF; Chiu JS; Chuang MH; Chiu JE; Lin CL
Asia Pac J Clin Nutr; 2008; 17(1):101-6. PubMed ID: 18364334
[TBL] [Abstract][Full Text] [Related]
28. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.
Akerele E; Levin FR
Am J Addict; 2007; 16(4):260-8. PubMed ID: 17661193
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
30. Clozapine protects bone mineral density in female patients with schizophrenia.
Lin CH; Huang KH; Chang YC; Huang YC; Hsu WC; Lin CY; Huang-Chih Chou F; Tsai GE; Lane HY
Int J Neuropsychopharmacol; 2012 Aug; 15(7):897-906. PubMed ID: 22014454
[TBL] [Abstract][Full Text] [Related]
31. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.
Abraham G; Paing WW; Kaminski J; Joseph A; Kohegyi E; Josiassen RC
Am J Psychiatry; 2003 Sep; 160(9):1618-20. PubMed ID: 12944336
[TBL] [Abstract][Full Text] [Related]
32. The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia.
Qiu J; Gong H; Wang B; Gu W; Wang L; Gu M; Zhang Y; Du X
Arch Osteoporos; 2020 Jun; 15(1):98. PubMed ID: 32601884
[TBL] [Abstract][Full Text] [Related]
33. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
34. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.
Meaney AM; Smith S; Howes OD; O'Brien M; Murray RM; O'Keane V
Br J Psychiatry; 2004 Jun; 184():503-8. PubMed ID: 15172944
[TBL] [Abstract][Full Text] [Related]
35. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Antipsychotics on Bone Mineral Density and Sex Hormones in Male Patients with Schizophrenia.
Bulut SD; Bulut S; Atalan DG; Tulaci RG; Türker T; Gürçay E; Aydemir Ç
Psychiatr Danub; 2016 Sep; 28(3):255-262. PubMed ID: 27658834
[TBL] [Abstract][Full Text] [Related]
37. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
[TBL] [Abstract][Full Text] [Related]
38. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
39. Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis.
Jhon M; Yoo T; Lee JY; Kim SY; Kim JM; Shin IS; Williams L; Berk M; Yoon JS; Kim SW
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29315805
[TBL] [Abstract][Full Text] [Related]
40. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.
Halbreich U
CNS Drugs; 2007; 21(8):641-57. PubMed ID: 17630817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
